Yuhan Wang

Yuhan Wang

Auto-generated profile, based on publicly available information

Yuhan Wang

Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YWYuhan Wang
Yuhan Wang
TYTailei Yuan
Tailei Yuan
LHLongyue He
Longyue He
JHJingjing Huang
Jingjing Huang
NWNodemsahajoel Wilfred
Nodemsahajoel Wilfred
CLCHanglian Lu
CHanglian Lu
Melittin is preclinically investigated as anticancer agent in multiple tumor types. But its regulation role and regulatory mechanism regarding NSCLC is unknown. In our investigation, Proteomic test was employed to identify proteins that expressed abnormally in cancer cells and that with Melittin treatmented. The results showed CTSB was one of the Top proteins with different expression levels in the lysosomes of Melittin-treatmented cancer cells and showed an up-regulation trend. CTSB expression was increased in NSCLC cancer tissues compared to adjacent normal tissues, as demonstrated in lung cancer tissue chips experiment. However, Melittin treatment increased the CTSB level in lysosomes, which inhibited the malignant progression of NSCLC. We hypothesized that the relative homeostasis of CTSB in cancer cells was destroyed, and CTSB exerts its hydrolytic effect excessively, resulting in excessive autophagy of cancer cells, thus inhibiting the malignant progression of cancer cells. The direct combination of Melittin and CTSB was proposed by molecular docking technique, LiP-SMap was used to analyze the target genes and active components extracted from high-throughput sequencing proteomic data, and successfully verified that melittin was successfully demonstrated to directly target CTSB-binding. In vivo and in vitro studies have shown that Melittin treatment inhibits the malignant progression of A549 and HCC1833 cells and animal tumors, namely non-small cell lung cancer, by promoting CTSB-mediated hyperautophagy. CTSB-specific inhibitor CA-074 Me and autophagy inhibitor 3-MA treatment reversed the inhibit effect of Melittin to the malignant progression of NSCLC. Taken together, Melittin treatment inhibited malignant progression regarding NSCLC through enhancing CTSB-mediated hyperautophagy.

14 November 2024 in European Journal of Pharmacology
Verified
Journal Article
Open access
YWYuhan Wang
Yuhan Wang
JYJiaying Yuan
Jiaying Yuan
JLJiao Liu
Jiao Liu
XLXiaodan Li
Xiaodan Li
CZChuanqiang Zhou
Chuanqiang Zhou
MJMingming Jin
Mingming Jin
Non-small cell lung cancer (NSCLC), although considered non-immunogenic, is often resistant to chemotherapy agents during the course of treatment in clinical patients. Melittin (C131H229N39O31, CAS: 20449-79-0), the major component of honey bee venom, is a promising anticancer drug. However, the mechanism employed by melittin to reverse chemotherapy resistance of NSCLC cells remains unknown. In this study, the Cell Counting Kit 8, ethynyl deoxyuridine assay, and other assays were utilized to elucidate the melittin effects upon cell proliferation. Proteomics, lung cancer (LC) tissue chip, and Western blot analysis were used to identify potential targets of melittin. A549/DDP cells were employed to investigate the melittin effects against cisplatin resistance. Also, an in vivo animal experiment was conducted to further clarify the regulatory function of melittin towards cisplatin resistance of A549/DDP cells. Results showed that melittin inhibited malignant progression of A549/DDP cells by down-regulation of pyruvate dehydrogenase kinase 3 (PDK3)-mediated aerobic glycolysis and inhibition of heat shock factor 1 (HSF1) expression. The therapeutic effect of melittin was increased by combination with KNK437 and impaired chemotherapy resistance regarding A549/DDP cells via reversing aerobic glycolysis. The in vivo experiments confirmed that melittin incremented A549/DDP cell cisplatin sensitivities. Collectively, the data suggested that melittin suppressed aerobic glycolysis by regulating HSF1/PDK3, which incremented cisplatin sensitivity of A549/DDP cells. It may provide a new treatment method for chemotherapy resistance in clinical NSCLC patients.


18 November 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
YWYuhan Wang
Yuhan Wang
XLXiaodan Li
Xiaodan Li
ZZZhangyan Zou
Zhangyan Zou
WYWenhui Yang
Wenhui Yang
MQMinxuan Qian
Minxuan Qian
MJMingming Jin
Mingming Jin
Background and aims Non-small cell lung cancer (NSCLC) accounts for > 80% of lung cancer cases, and its mortality is predominantly attributed to its metastatic nature. Therefore, developing novel therapeutic drugs and treatment methods to improve the prognosis of patients with NSCLC is critical. Purpose This study examined the effect of Melittin (MEL) on NSCLC metastasis and explored the underlying regulatory mechanisms. Methods The effects of different doses of MEL on NSCLC cells was examined using Transwell and wound healing assays. RT-qPCR and western blotting were performed to assess the mRNA and protein expression of proteasome 20S subunit alpha 7 (PSMA7) and epithelial-mesenchymal transition-related genes such as E-cadherin and N-cadherin. A PSMA7 overexpressing lentiviral vector was constructed and transfected into HCC1833 and A549 cells to examine the inhibitory effect of MEL on NSCLC malignant progression. Proteomics analyses were performed to identify differentially expressed proteins in NSCLC cells following MEL treatment. The potential involvement of the ubiquitin degradation pathway was examined using cycloheximide and MG132. Co-immunoprecipitation (Co-IP) assays were performed to detect interactions between PSMA7, ubiquitin-specific peptidase (USP)-10, and ring finger protein (RNF)-20. An in vivo lung metastasis model was used to evaluate the effects of MEL on NSCLC metastasis.